Thursday, May 17, 2018 - 07:00
  • Preliminary activity observed in patients with recurrent/metastatic microsatellite-stable colorectal cancer (MSS-CRC), a population historically unresponsive to PD-1/L1 blockade
  • 3 partial responses (PR) and 11 stable disease (SD) response among 37 patients evaluable for efficacy – disease control rate (DCR) at 16 weeks was 24%
  • Manageable toxicity profile demonstrated
  • Updated clinical data will be presented at ASCO


Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) last night announced preliminary data from an ongoing Phase I dose escalation and expansion study evaluating the safety and efficacy of the combination of monalizumab, a first-in-class monoclonal antibody targeting NK- and T cell checkpoint receptor NKG2A, with durvalumab.

Data show preliminary anti-tumor activity in patients with recurrent, metastatic colorectal cancer, with 3 partial responses and 11 stable disease responses among 37 patients evaluable for efficacy, with a disease control rate of 24% at 16 weeks (data cut as of February 8, 2018). The data also showed a manageable toxicity profile.

The Phase I dose escalation and expansion study enrolled a total of 55 patients. In the dose-escalation part, 15 patients with selected solid tumors received durvalumab 1500 mg every 4 weeks in combination with monalizumab at increasing doses. In the expansion phase, 40 patients with microsatellite-stable colorectal cancer (MSS-CRC) were enrolled. 58% of patients in expansion had 3+ lines of prior therapy.

These data were highlighted in an abstract (#3540) published online on May 16 by the American Society of Clinical Oncology (ASCO) in advance of its annual meeting in Chicago, Illinois, June 1-5, 2018. The abstract is available on the ASCO website. A poster (#33) with updated clinical data will be presented at ASCO in the Gastrointestinal (Colorectal) Cancer session in Hall A on Sunday, June 3 between 8:00am and 11:30am.

Based on these preliminary results, Innate’s partner AstraZeneca/MedImmune progressed the combination with standard of care therapies.

PR in English106.25 KB
CP en français110.1 KB